HealthEquity Reports Strong Q1, Raises FY27 Guidance, and Boosts Share Buyback Program by $1.0 Billion
HQY sits 26% above its 52-week low of $72.76.
Summary
HealthEquity reported strong Q1 financial results, raised its full-year guidance, and authorized an additional $1.0 billion for its share repurchase program, signaling strong performance and management confidence.
Key Events · Earnings and Guidance · HQY
-
Strong Q1 Financial Performance
HealthEquity reported Q1 revenue of $354.6 million (up 7% year-over-year), net income of $69.4 million (up 29%), and diluted EPS of $0.82 (up 34%). Adjusted EBITDA increased 17% to $164.5 million, with margins expanding to 46%.
-
Raised Fiscal Year 2027 Guidance
Management raised its full fiscal year 2027 outlook, now expecting revenues between $1.410 billion and $1.420 billion, net income between $242 million and $248 million, and non-GAAP diluted EPS between $4.66 and $4.73.
-
Significant Share Repurchase Program Expansion
The board of directors authorized an additional $1.0 billion for common stock repurchases, significantly expanding the existing program. The company repurchased 1.5 million shares for $123.0 million during Q1.
-
Continued HSA Asset Growth
Total HSA Assets grew 19% year-over-year to $37.1 billion as of April 30, 2026, reflecting strong account and asset growth.
Analysis · HQY · Trade & Services
HealthEquity delivered robust first-quarter results, exceeding prior year performance across key financial metrics and demonstrating strong operational leverage with expanding Adjusted EBITDA margins. The company also raised its full fiscal year 2027 guidance, signaling increased confidence in its future performance. Most notably, the board authorized an additional $1.0 billion for its share repurchase program, a substantial commitment to returning capital to shareholders, representing a significant portion of the company's market capitalization.
At the time of this filing, HQY was trading at $91.50 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $72.76 to $116.65. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.